Prognostic and predictive markers in canine tumours: Rationale and relevance. A review

Veterinary Quarterly

Volumn 27, Issue 2, 2005, Pages 52-64

  Mukaratirwa, S ^a  

^a University of Zimbabwe   (United States)

Author keywords

Adhesion molecules; Angiogenesis; Apoptosis; Canine neoplasms; Cell cycle; Dog diseases; Molecular markers; P53 protein; Prognosis; Prognostic and predictive markers; Proliferation; Proliferation markers; Tumour behaviour; Tumour grading; Tumour markers; Tumour staging; Tumours; Veterinary oncology

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER; ARGYROPHILIC NUCLEOLAR ORGANIZER REGION PROTEIN; BETA CATENIN; BROXURIDINE; CELL ADHESION MOLECULE; CYCLINE; HYALURONIC ACID; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; MOLECULAR MARKER; NUCLEAR PROTEIN; PIROXICAM; PROTEIN P53; SCLEROPROTEIN; TENASCIN; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG; UVOMORULIN; VERSICAN; VINCRISTINE SULFATE;

ANIMAL; ANIMAL DISEASE; APOPTOSIS; DOG; DOG DISEASE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PROGNOSIS; REVIEW; ANGIOGENESIS; CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL CYCLE; CELL PROLIFERATION; CLINICAL FEATURE; DENSITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MICROVASCULATURE; MITOSIS INDEX; MOLECULAR DYNAMICS; NONHUMAN; PREDICTION; RELIABILITY; TREATMENT OUTCOME; TUMOR VASCULARIZATION; VETERINARY MEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DOG DISEASES; DOGS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

CANIS FAMILIARIS;

EID: 21444438813     PISSN: 01652176     EISSN: 18755941     Source Type: Journal    
DOI: 10.1080/01652176.2005.9695186     Document Type: Article

References (114)

1. Abadie JJ, Amardeilh MA and Delverdier ME. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. Journal of the American Veterinary Medical Association 1999; 215: 1629–1634.
2. Agarwal ML, Taylor WR, Chernov MV, Chernova OB and Stark GR. The p53 network. Journal of Biological Chemistry 1998; 273: 1–4.
3. Auvinen P. Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M and Kosma VM. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. American Journal of Pathology 2000: 156; 529–535.
4. Bostock DE, Crocker J, Harris K and Smith P. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. British Journal of Cancer 1989; 59: 915–918.
5. Bostock DE and Dye MT. Prognosis after surgical excision of canine fibrous connective tissue sarcomas. Veterinary Pathology 1980; 17: 581–588.
6. Bostock DE. Prognosis after surgical excision of canine melanomas. Veterinary Pathology 1979; 16: 32–40.
7. Bratulic M, Grabarevic Z, Artukovic B and Capak D. Number of nucleoli and nucleolar organizer regions per nucleus and nucleolus--prognostic value in canine mammary tumors. Veterinary Pathology 1996; 33: 527–532.
8. Bravo R, Frank R, Blundell PA and Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987; 326: 515–517.
9. Bravo R and Macdonald-Bravo H. Changes in the nuclear distribution of cyclin (PCNA) but not its synthesis depend on DNA replication. EMBO Journal 1985; 4: 655–661.
10. Brown PJ, Rema A and Gartner F. Immunohistochemical characteristics of canine aortic and carotid body tumours. Journal of Veterinary Medicine A. Physiology, Pathology, Clinical Medicine 2003; 50: 140–144.
11. Brunetti B, Sarli G, Preziosi R, Leprotti S and Benazzi C. E-cadherin expression in canine mammary carcinomas with regional lymph node metastases. Journal of Veterinary Medicine A. Physiology, Pathology, Clinical Medicine 2003; 50: 496–500.
12. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J and Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-tixed paraffin sections. Journal of Pathology 1992; 168: 357–363.
13. Della Saida L, Preziosi R, Mazzoni M and Marcato PS. Cell proliferation patterns in canine infundibular keratinizing acanthorna and well differentiated squamous cell carcinoma of the skin. European Journal of Histochemistry 2002; 46: 165–172.
14. Destexhe E, Vanmanshoven P and Coignoul F. Comparison of argyrophilic nucleolar organizer regions by counting and image analysis in canine mammary tumors. American Journal of Veterinary Research 1995; 56: 185–187.
15. De Vico G, Agrimi U and Maiolino P. Nucleolar size and mitotic index in basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of canine skin. Zentralblatt fur Veterinarmedizin. Reihe A 1994; 41: 76–79.
16. Erdelyi I, Nieskens DH, van Dijk JE Vass L and Nederbragt H. Immunohistochemical evaluation of versican, in relation to chondroitin sulphate, in canine mammary tumours. Histology and Histopathology 2003; 18: 1067–1080.
17. Evanko SP, Angello JC and Wight TN. Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 1999; 19: 1004–1013.
18. Faustino AM, van Garderen E, Schalken JA and Nederbragt H. Tenascin expression in normal, hyperplastic, dysplastic and neoplastic canine mammary tissues. Journal of Comparative Pathology 2002; 126: 1–8.
19. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539–542.
20. Folkman J. What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 1990; 82: 4–6.
21. Fournel-Fleury C, Magnol JP, Chabanne L, Ghernati I, Marchal T, Bonnefond C, Bryon PA and Felman P. Growth fractions in canine non-Hodgkin’s lymphomas as determined in situ by the expression of the Ki-67 antigen. Journal of Comparative Pathology 1997; 117: 61–72.
22. Funakoshi Y, Nakayama H, Uetsuka K, Nishimura R, Sasaki N and Doi K. Cellular proliferative and telomerase activity in canine mammary gland tumors. Veterinary Pathology 2000; 37: 177–183.
23. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H. Cell cycle analysis of a cell proliferationassociated human nuclear antigen defined by the monoclonal antibody Ki-67. Journal of Immunology 1984; 133: 1710–1715.
24. Ginn PE, Fox LE, Brower JC, Gaskin A, Kurzman ID and Kubilis PS. Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors. Veterinary Pathology 2000; 37: 33–39.
25. Gonzalez CM, Griffey SM, Naydan DK, Flores E, Cepeda R, Cattaneo G and Madewell BR. Canine transmissible venereal tumour: a morphological and immunohistochemical study of 11 tumours in growth phase and during regression after chemotherapy. Journal of Comparative Pathology 2000; 122: 241–248.
26. Graham JC and Myers RK. The prognostic significance of angiogenesis in canine mammary tumors. Journal of Veterinary Internal Medicine 1999; 13: 416–418.
27. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 1982; 218: 474–475.
28. Graves GM, Bjorling DE and Mahaffey E. Canine hemangiopericytoma: 23 cases (1967-1984). Journal of the American Veterinary Medical Association 1988; 192: 99–102.
29. Griffey SM, Kraegel SA and Madewell BR. Proliferation indices in spontaneous canine lung cancer: proliferating cell nuclear antigen (PCNA), Ki-67 (MIB1) and mitotic counts. Journal of Comparative Pathology 1999; 120: 321–332.
30. Guvenc T, Haligur M, Orman MN and Haziroglu R. Mitosis and apoptosis in canine cutaneous histiocytomaand transmissible venereal tumour. Acta Veterinaria Hungarica 2002; 50: 315–321.
31. Harmelin A, Zuckerman A and Nyska A. Correlation of Ag-NOR protein measurements with prognosis in canine transmissible venereal tumour. Journal of Comparative Pathology 1995; 1 12: 429–433.
32. Hinrichs U, Rutteman GR and Nederbragt H. Stromal accumulation of chondroitin sulphate in mammary tumours of dogs. British Journal of Cancer 1999; 80: 1359–1365.
33. Hojilla CV, Mohammed FF and Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. British Journal of Cancer 2003; 89: 1817–1821.
34. Hung C, Pong VF, Cheng CR, Wong FI and Chu RM. An improved system for quantifying AgNOR and PCNA in canine tumors. Anticancer Research 2000; 20: 3273–3280.
35. Inoue M and Wada N. Immunohistochemical detection of p53 and p21 proteins in canine testicular tumours. Veterinary Record 2000; 146: 370–372.
36. Ioachim E. Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ and Pavlidis N. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. European Journal of Cancer 2002; 38: 2362–2370.
37. Jaffe MH, Hosgood G, Taylor HW, Kerwin SC, Hedlund CS, Lopez MK, Davidson JR, Miller DM and Paranjpe M. Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors. Veterinary Pathology 2000; 37: 40–46.
38. Johnson GC, Miller MA and Ramos-Vara JA. Comparison of argyrophilic nucleolar organizer regions (AgNORs) and mitotic index in distinguishing benign from malignant canine smooth muscle tumors and in separating inflammatory hyperplasia from neoplastic lesions of the urinary bladder mucosa. Journal of Veterinary Diagnostic Investigation 1995; 7: 127–136.
39. Juntes P and Pogacnik M. Morphometric analysis of AgNORs in tubular and papillary parts of canine mammary gland tumors. Analytical and Quantitative Cytology and Histology 2000; 22: 185–192.
40. Kerr JFR, Winterford CM and Harmon BV. Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013–20126.
41. Keshgegian AA and Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and. MIB-1. American Journal of Clinical Pathology 1995; 104: 42–49.
42. Kiupel M, Bostock D and Bergmann V. The prognostic significance of AgNOR counts and PCNA-positive cell counts in canine malignant lymphomas. Journal of Comparative Pathology 1998; 119: 407–418.
43. Kiupel M, Teske E and Bostock D. Prognostic factors for treated canine malignant lymphoma. Veterinary Pathology 1999; 36: 292–300.
44. Knudson CB and Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB Journal 1993; 7: 1233–1241.
45. Koukoulis GK, Gould VE, Bhattacharyya Gould JE. Howeedy AA and Virtanen I. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Human Pathology 1991; 22: 636–643.
46. Kressner U, Lindmark G, Tomasini-Johansson B, Bergstrom R, Gerdin B, Pahlman L and Glimelius B. Stromal tenascin distribution as a prognostic marker in colorectal cancer. British Journal of Cancer 1997; 76: 526–530.
47. Lana SE, Ogilvie GK and Hansen RA. Identification of matrix metalloproteinases in canine neoplastic tissue. American Journal of Veterinary Research 2000; 61: 111–114.
48. Laprie C, Abadie J, Amardeilh MF, Net JL, Lagadic M and Delverdier M. MIB-1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma. Veterinary Dermatology 2001; 12: 139–147.
49. Lee CH, Kim WH, Lim JH, Kang MS, Kim DY and Kweon OK. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. Journal of Veterinary Science 2004; 5: 63–69.
50. Leibman NF, Lana SE, Hansen RA, Powers BE, Fettman MJ, Withrow SJ and Ogilvie GK. Identification of matrix metalloproteinases in canine cutaneous mast cell tumors. Journal of Veterinary Internal Medicine 2000, 14: 583–586.
51. Lipponen PK and Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. Journal of Pathology 1994; 173: 333–339.
52. Lohr CV, Teitke JP, Failing K, Weiss E. Characterization of the proliferation state in canine mammary tumors by the standardized AgNOR method with postfixation and immunohistologic detection of Ki-67 and PCNA. Veterinary Pathology 1997; 34: 212–221.
53. Loukopoulos P. Mungall BA, Straw RC, Thornton JR and Robinson WF. Matrix metalloproteinase-2 and -9 involvement in canine tumors. Veterinary Pathology 2003; 40: 382–394.
54. Loukopoulos P, Thornton JR and Robinson WF. Clinical and pathologic relevance of p53 index in canine osseous tumors. Veterinary Pathology 2003; 40: 237–248.
55. Maiolino P. Papparella S. Restucci B and De Vico G. Angiogenesis in squamous cell carcinomas of canine skin: an immunohistochemical and quantitative analysis. Journal of Comparative Pathology 2001; 125: 117–121.
56. Maiolino P, Restucci B and De Vico G. Expression of proliferating cell nuclear antigen in basal cell carcinomas and in squamous cell carcinomas of canine skin: correlation with mitotic index and histological features. Zentralblatt fur Veterinarmedizin. Reihe A 1995; 42: 339–343.
57. McEntee MF and Brenneman KA. Dysregulation of betacatenin is common in canine sporadic colorectal tumors. Veterinary Pathology 1999; 36: 228–236.
58. Millanta F, Fratini F, Corazza M, Castagnaro M, Zappulli V and Poli A. Proliferation activity in oral and cutaneous canine melanocytic tumours: correlation with histological parameters, location, and clinical behaviour. Research in Veterinary Science 2002; 73: 45–51.
59. Minkus G, Jutting U, Aubele M, Rodenacker K, Gais P, Breuer W and Hermanns W. Canine neuroendocrine tumors of the pancreas: a study using image analysis techniques for the discrimination of metastatic versus nonmetastatic tumors. Veterinary Pathology 1997; 34: 138–145.
60. Mohammed SI, Bennett PF, Craig BA, Glickman W, Mutsaers AJ, Snyder PW, Widmer WR, DeGortari AE, Bonney PL and Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Research 2002; 62: 356–358.
61. Mukaratirwa S, Chimonyo M, Obwolo M, Gruys E and Nederbragt H. Stromal cells and extracellular matrix components in spontaneous canine transmissible venereal tumour at different stages of growth. Histology and Histopathology 2004; 19: 1117–1123.
62. Mukaratirwa S, de Witte E, van Ederen AM and Nederbragt H. Tenascin expression in relation to stromal tumour cells in canine gastrointestinal epithelial tumours. Journal of Comparative Pathology 2003; 129: 137–146.
63. Mukaratirwa S, van Ederen AM, Gruys E and Nederbragt H. Versican and hyaluronan expression in canine colonic adenomas and carcinomas: relation to malignancy and depth of tumour invasion. Journal of Comparative Pathology 2004; 131: 259–270.
64. Naik P, Karrim J and Hanahan D. The rise and fall of apoptosis during multistage tumorigenesis: downmodulation contributes to tumor progression from angiogenic progenitors. Genes and Development 1996; 10: 2105–2116.
65. Nasir L, Rutteman GR, Reid SW, Schulze C and Argyle DJ. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas. Cancer Letters 2001; 174: 83–89.
66. Nieto A, Pena L, Perez-Alenza MD, Sanchez MA, Flores JM and Castano M. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Veterinary Pathology 2000; 37: 239–247.
67. O’Connell J, Bennett MW, O’Sullivan GC, Roche D, Kelly J, Collins JK and Shanahan F. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. Journal of Pathology 1998; 186: 240–246.
68. Ogura E, Senzaki H and Kiyozuka Y. Expression and localization of matrix metalloproteinases and tissue inhibitors of metalloproteinases as a prognostic factor in advanced colorectal carcinomas. Oncology Reports 1997; 4: 701–705.
69. Ohta G, Sakai H, Kachi S, Hirata A, Yonemaru K, Kitajima A, Yanai T and Masegi T. Assessment of proliferative potentials of canine osteosarcomas and chondrosarcomas by MIB-1 immunohistochemistry and bromodeoxyuridine incorporation. Journal of Comparative Pathology 2004; 131: 18–27.
70. Papparella S, Restucci B, and Maiolino P. Immunohistochemical distribution of type IV collagenase in normal, dysplastic and neoplastic canine mammary gland. Journal of Comparative Pathology 1997; 117: 277–282.
71. Pardee AB. GI events and regulation of cell proliferation. Science 1989; 246: 603–608.
72. Pena LL, Nieto AI, Perez-Alenza D, Cuesta P and Castano M. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. Journal of Veterinary Diagnostic Investigation 1998; 10: 237–246.
73. Phillips BS, Kass PH, Naydan DK, Winthrop MD, Griffey SM and Madewell, BR. Apoptotic and proliferation indexes in canine lymphoma. Journal of Veterinary Diagnostic Investigation 2000; 12: 111–117.
74. Platz SJ, Breuer W, Pfleghaar S. Hermanns W. Prognostic value of grading in canine extramedullary Veterinary Pathology 1999; 36: 23–27.
75. Preziosi R, Sarli G, Benazzi C and Marcato PS. Detection of proliferating cell nuclear antigen (PCNA) in canine and feline mammary tumours. Journal of Comparative Pathology 1995; 113: 301–313.
76. Preziosi R, Sarli G and Paltrinieri M. Prognostic value of intratumoral vessel density in cutaneous mast cell tumors of the dog. Journal of Comparative Pathology 2004; 130: 143–151.
77. Prokocimer M and Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell 84: 2391–2411.
78. Reis AL, Carvalheira J, Schmitt Immunohistochemical study of E-cadherin in canine mammary Record 2003; 152: 621–624.
79. Restucci B, De Vico G and Maiolino P. Evaluation of angiogenesis in canine mammary tumors by quantitative platelet endothelial cell adhesion molecule immunohistochemistry. Veterinary Pathology 2000; 37: 297–301.
80. Restucci B, Maiolino P. Paciello O, Martano M, De Vico G and Papparella S. Evaluation of angiogenesis in canine seminomas by quantitative immunohistochemistry. Journal of Comparative Pathology 2003; 128; 252–259.
81. Restucci B, Papparella S. De Vico G and Maiolino P. cadherin expression in normal and neoplastic canine mammary gland. Journal of Comparative Pathology 1997; 116: 191–202.
82. Restucci B, Papparella S, Maiolino P and De Vico G. Expression of vascular endothelial growth factor in canine Minkus G and histopathological plasmacytomas. lineages. Blood 1994; FC, and Gartner F. the expression of tumours. Veterinary mammary tumors. 488–493.
83. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM and Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. Journal of the National Cancer Institute 2003; 95: 661–668
84. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG and Horsfall DJ. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clinical Cancer Research 2002; 8: 1054–1060.
85. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR and Horsfall D. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clinical Cancer Research 1998; 4: 963–971.
86. Roels S, Tilmant K and Ducatelle R. expression and apoptosis in melanomas of dogs and cats. Research in Veterinary Science 2001; 70: 19–25.
87. Roels S. Tilmant K and Ducatelle R. PCNA and Ki-67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs. Journal of Comparative Pathology 1999; 121: 13–24.
88. Ropponen K, Tammi M, Parkkinen J, Eskelinen M, Tammi R, Lipponen P, Agren U, Alhava E and Kosma VM. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Research 1998; 58: 342–347.
89. Rudas M, Gnant MF, Mittlbock M, Neumayer R, Kummer A, Jakesz R, Reiner G and Reiner A. Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Research and Treatment 1994; 32: 165–175.
90. Sagartz JE, Bodley WL, Gamblin RM, Couto CG, Tierney LA and Capen CC. p53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Veterinary Pathology 1996; 33: 213–2121.
91. Sakai H, Noda A, Shirai N, Iidaka T, Yanai T, Masegi T, Shirai N, Iidaka T, Yanai T and Masegi T. Proliferative activity of canine mast cell tumours evaluated by bromodeoxyuridine incorporation and Ki-67 expression. Journal of Comparative Pathology 2002; 127: 233–238.
92. Sarli G, Benazzi C, Preziosi R and Marcato PS. Proliferative activity assessed by anti-PCNA and Ki-67 monoclonal antibodies in canine testicular tumours. Journal of Comparative Pathology 1994; 110: 357–368.
93. Sarli G, Preziosi R, Benazzi C, Castellani G, Marcato PS. Prognostic value of histologic stage and proliferative activity in canine malignant mammary tumors. Journal Veterinary Diagnostic Investigation 2002; 14: 25–34.
94. Schweyer S, Soruri A, Meschter O, Heintze A, Zschunke F, Miosge N, len P. Schlott T, Radzun HJ and Fayyazi A. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. British Journal of Cancer 2004; 91: 589–598.
95. Setoguchi A, Sakai T, Okuda M, Minehata K, Yazawa M, Ishizaka T, Watari T, Nishimura R, Sasaki N, Hasegawa A and Tsujimoto H. Aberrations of the p53 tumor suppressor gene in various tumors in dogs. American Journal of Veterinary Research 2001; 62: 433–439.
96. Siitonen SM, Kononen JT, He lin HJ, Rantala IS, Holli KA and Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. American Journal of Clinical Pathology 1996; 105: 394–402.
97. Simoes JP, Schoning P and Butine M. Prognosis of canine mast cell tumors: a comparison of three methods. Veterinary Pathology 1994; 31: 637–647.
98. Sirri V, Roussel P and Hernandez-Verdun D. The AgNOR proteins: qualitative and quantitative changes during the cell cycle. Micron 2000; 31: 121–126.
99. Spangler WL, Culbertson MR and Kass PH. Primary mesenchymal (nonangiomatous/nonlymphomatous) neoplasms occurring in the canine spleen: anatomic classification, immunohistochemistry, and mitotic activity correlated with patient survival. Veterinary Pathology 1994; 31: 37–47.
100. Stearns M and Stearns ME. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncology Research 1996; 8: 69–75.
101. Sueiro FA, Alessi AC and Vassal lo J. Canine lymphomas: a morphological and immunohistochemical study of 55 cases, with observations on p53 immunoexpression. Journal of Comparative Pathology 2004; 131: 207–213.
102. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Current Opinion in Cell Biology 1993; 5: 806–811.
103. Talvensaari-Mattila A, Paakko P and Hoyhtya M. Matrix metalloproteinase-2 immunoreactive protein. A marker of aggressiveness in breast carcinoma. Cancer 1998; 83: 1153–1162.
104. Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K and Muraoka R. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Research 1997; 57: 1043–1046.
105. Theon AP, Lecouteur RA, Carr EA and Griffey SM. Influence of tumor cell proliferation and sex-hormone receptors on effectiveness of radiation therapy for dogs with incompletely resected meningiomas. Journal of American Veterinary Medical Association 2000; 216: 701-707, 684–685.
106. Toi M, Kashitami J and Tominaga T. Tumour angiogenesis is an independent prognostic indicator of breast carcinoma. International Journal of Cancer 1993; 55: 371–374.
107. Vail DM, Kisseberth WC, Obradovich JE, Moore FM, London CA, MacEwen EG and Ritter MA. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin’s lymphoma. Experimental Hematology 1996; 24: 807–815.
108. Wakui S, Muto T, Yokoo K, Yokoo R, Takahashi H, Masaoka T, Hano H and Furusato M. Prognostic status of p53 gene mutation in canine mammary carcinoma. Anticancer Research 2001; 21: 611–616.
109. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. American Journal of Pathology 1993; 143: 401–409.
110. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K and Haglund C. Tenascin-C expression correlates with prognosis in gastric cancer. Oncology 2003; 64: 245–250.
111. Wolf JC, Ginn PE, Homer B, Fox LE and Kurzman ID. Immunohistochemical detection of p53 tumor suppressor gene protein in canine epithelial colorectal tumors. Veterinary Pathology 1997; 34: 394–404.
112. Wyllie AH, Kerr JFR and Currie AR. Cell death: the significance of apoptosis. International Review of Cytology 1980; 68: 251–304.
113. Yoshida K, Yanai T, Iwasaki T, Sakai H, Ohta J, Kati S, Ishikawa K, Lackner AA and Masegi T. Proliferative potential of canine oral epulides and malignant neoplasms assessed by bromodeoxyuridine labeling. Veterinary Pathology 1999; 36: 35–41.
114. Zuccari DA, Santana AE, Cury PM and Cordeiro JA. Immunocytochemical study of Ki-67 as a prognostic marker in canine mammary neoplasia. Veterinary Clinical Pathology 2004; 33: 23–28.